Insider Selling: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Sells $24,470.80 in Stock

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTGet Free Report) General Counsel Martin Wilson sold 1,048 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $23.35, for a total transaction of $24,470.80. Following the sale, the general counsel now directly owns 65,762 shares in the company, valued at $1,535,542.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Martin Wilson also recently made the following trade(s):

  • On Thursday, February 29th, Martin Wilson sold 4,100 shares of Rocket Pharmaceuticals stock. The stock was sold at an average price of $29.33, for a total value of $120,253.00.

Rocket Pharmaceuticals Stock Up 0.5 %

Shares of RCKT stock opened at $22.44 on Thursday. The stock’s 50 day simple moving average is $24.43 and its 200 day simple moving average is $26.09. Rocket Pharmaceuticals, Inc. has a twelve month low of $14.89 and a twelve month high of $32.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.47 and a quick ratio of 10.47.

Rocket Pharmaceuticals (NASDAQ:RCKTGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.01. During the same period last year, the company posted ($0.73) EPS. As a group, equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RCKT. Wellington Management Group LLP boosted its holdings in Rocket Pharmaceuticals by 56.0% during the third quarter. Wellington Management Group LLP now owns 8,022,830 shares of the biotechnology company’s stock valued at $164,388,000 after acquiring an additional 2,880,373 shares during the period. Janus Henderson Group PLC boosted its stake in Rocket Pharmaceuticals by 174.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,606,016 shares of the biotechnology company’s stock valued at $70,170,000 after purchasing an additional 1,656,111 shares during the period. Vanguard Group Inc. grew its holdings in Rocket Pharmaceuticals by 18.3% in the 4th quarter. Vanguard Group Inc. now owns 5,447,565 shares of the biotechnology company’s stock valued at $163,264,000 after buying an additional 843,552 shares during the last quarter. Westfield Capital Management Co. LP increased its position in Rocket Pharmaceuticals by 14.7% in the 3rd quarter. Westfield Capital Management Co. LP now owns 4,193,996 shares of the biotechnology company’s stock worth $85,935,000 after buying an additional 538,209 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Rocket Pharmaceuticals by 105.1% during the third quarter. Assenagon Asset Management S.A. now owns 877,140 shares of the biotechnology company’s stock worth $17,973,000 after buying an additional 449,569 shares during the last quarter. Institutional investors own 98.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RCKT shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, February 27th. The Goldman Sachs Group started coverage on shares of Rocket Pharmaceuticals in a report on Tuesday, April 2nd. They set a “neutral” rating and a $39.00 price target for the company. UBS Group dropped their price objective on shares of Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday, March 1st. StockNews.com raised shares of Rocket Pharmaceuticals to a “sell” rating in a research note on Friday, February 9th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $52.13.

Get Our Latest Stock Report on RCKT

Rocket Pharmaceuticals Company Profile

(Get Free Report)

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

See Also

Insider Buying and Selling by Quarter for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.